Pre-Made Sargramostim Biosimilar, Recombinant Protein targeting CSF2RA: Recombinant therapeutic protein targeting CD116/CDw116/CSF2R/CSF2RAX/CSF2RAY/CSF2RX/CSF2RY/GM-CSF-R-alpha/GMCSFR/GMCSFR-alpha/GMR/GMR-alpha/SMDP4/alphaGMR for drug discovery and mechanism of action (MOA) research

Pre-Made Sargramostim Biosimilar, Recombinant Protein targeting CSF2RA: Recombinant therapeutic protein targeting CD116/CDw116/CSF2R/CSF2RAX/CSF2RAY/CSF2RX/CSF2RY/GM-CSF-R-alpha/GMCSFR/GMCSFR-alpha/GMR/GMR-alpha/SMDP4/alphaGMR is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sargramostim (tradename Leukine) is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator.

Sargramostim is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. Sargramostim therapy has been promising in the adjuvant setting with vaccines and for anti-microbial-resistant infections and treating autoimmune pulmonary alveolar proteinosis and gastrointestinal, peripheral arterial and neuro-inflammatory diseases. It also may be useful as an adjuvant in anti-cancer immunotherapy. Sargramostim increases the cytotoxic activity of monocytes toward certain malignant cell lines and activates polymorphonuclear neutrophils to inhibit the growth of cancer cells. GM-CSF can stimulate the proliferation of leukemias; most require GM-CSF as a growth factor.